Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ��� 50%: EMPOWER-Lung 1 subgroup analysis.

Citation

• Ozguroglu, M., Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Gogishvili, M., . . . Rietschel, P. (2021). Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ��� 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 39(15_suppl), 9085. doi:10.1200/jco.2021.39.15_suppl.9085

Digital Object Identifier (doi)

• 10.1200/jco.2021.39.15_suppl.9085

Web Of Science Accession Number

Start Page

• 9085

End Page

• 9085

Volume

• 39

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2021

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Ozguroglu, M., Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Gogishvili, M., . . . Rietschel, P. (2021). Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ��� 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 39(15_suppl), 9085. doi:10.1200/jco.2021.39.15_suppl.9085

Digital Object Identifier (doi)

• 10.1200/jco.2021.39.15_suppl.9085

Web Of Science Accession Number

Start Page

• 9085

End Page

• 9085

Volume

• 39

Issue

• 15_suppl

Place Of Publication